Stock market announcement archive

May 8, 2024
Bergen, Norway, May 5th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q1 financial report and operational update. Lifecare Q1 report 2024 is available here Lifecare has been delivering milestones on a continuous basis over a long period. The company has […]
Read more
April 26, 2024
Bergen, Norway 26 April 2024: Hannibal Invest AS, a company closely associated with Hans Hekland, member of the Board of Directors of LifeCare AS (the “Company”), has on 26 April 2024 sold 150,000 shares in the Company at an average price of NOK 3.05 per share. Following this transaction, Hannibal Invest AS holds 50,000 shares […]
Read more
April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more
April 26, 2024
Correted item: Date of extraordinary meeting now consistently stated as 16 May 2024 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. […]
Read more
April 25, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement published […]
Read more
April 25, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF […]
Read more
April 9, 2024
Bergen, Norway, April 9th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Annual Report 2023. – The technology development and company progress were fantastic in 2023. We expect nothing less in 2024, in our mission to make life easier for patients […]
Read more
April 3, 2024
Bergen, Norway, 3rd April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully reached the target for pilot production of the Sencell sensor. Reports show a breakthrough, and this will pave the way for the automated production by end of Q2 as scheduled. Reference […]
Read more
March 21, 2024
Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has notified that they will grant for a new patent to Lifecare. Reference is made to stock exchange notification November 8th, 2023, that EPO intended […]
Read more
March 5, 2024
Bergen, Norway, 5 March 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a cleanroom. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th, 2023 and later […]
Read more